Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California. Show more
Location: 1150 Veterans Boulevard, South San Francisco, CA, 94080, United States | Website: https://www.nkartatx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
117.8M
52 Wk Range
$1.31 - $8.23
Previous Close
$1.66
Open
$1.68
Volume
505,102
Day Range
$1.64 - $1.70
Enterprise Value
-68.81M
Cash
265.5M
Avg Qtr Burn
-25.2M
Insider Ownership
5.02%
Institutional Own.
91.72%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NKX019 (CAR NK cell therapy) Details Systemic lupus erythematosus, Autoimmune disease | Phase 1 Data readout | |
NKX019 Details Myasthenia gravis | Phase 1 Data readout | |
NKX019 (CAR NK cell therapy) Details B-cell malignancies, Non-Hodgkin lymphoma, B-cell lymphoma | Phase 1 Data readout | |
NKX019 (CAR NK cell therapy) Details Lupus nephritis | Phase 1 Data readout | |
NKX019 (CAR NK cell therapy) Details Systemic sclerosis, Idiopathic inflammatory myopathy / myositis, ANCA-Associated Vasculitis | Phase 1 Data readout | |
NKX101 (CAR-T targeting NKG2D) Details Bone marrow disorder, Acute myeloid leukemia, Cancer, Myelodysplastic syndrome | Failed Discontinued |